Guedes Vânia, Bettencourt-Silva Rita, Queirós Joana, Esteves Maria da Luz, Teles Maria José, Carvalho Davide
Family Medicine, Unidade de Saúde Familiar Faria Guimarães, Rua Faria Guimarães 915/931, 4200-292, Porto, Portugal.
Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar de São João E.P.E, Porto, Portugal.
J Med Case Rep. 2017 Jul 26;11(1):201. doi: 10.1186/s13256-017-1377-1.
Hemoglobin A1c is used to evaluate the glycemic control in patients with diabetes and is a risk marker for chronic complications of diabetes. Hemoglobin variants are reported to falsely lower or increase hemoglobin A1c test results. We present a case report of a patient with diabetes with discrepancy between fasting plasma glucose and hemoglobin A1c due to the presence of hemoglobin Himeji, a clinically silent and very rare hemoglobinopathy.
A 76-year-old white woman, born and living in Portugal, with type 2 diabetes presented to the family physician for a routine visit. She had no active complaints, including history or symptoms of hypoglycemia, and her physical examination was unremarkable. A review of her laboratory data showed fasting plasma glucose of 190 mg/dL and a hemoglobin A1c of 4.1%. The remaining blood test results were clinically insignificant; a further review of her laboratory data over the past 4 years revealed that her fasting plasma glucose had ranged from 130 to 250 mg/dL and hemoglobin A1c was consistently lower than 5%. A study of hemoglobins detected 32.8% of abnormal hemoglobin. Genetic sequencing identified a heterozygous mutation compatible with hemoglobin Himeji (c.422C>A; p.Ala141Asp). We tracked her family (three sons, six grandchildren, and two greatgrandchildren) for the presence of this hemoglobin variant, but none had this hemoglobinopathy.
Despite the advantages of hemoglobin A1c in the follow-up and treatment of diabetes, the factors that interfere with its results must be known to ensure a correct estimation of the degree of glycemic control and a proper management of the disease. Therefore, health professionals should suspect the existence of hemoglobin variants when: the hemoglobin A1c value is above 15% or below the lower limit of its reference interval; there is a significant modification in its result coinciding with a change in assay methods; and there is a low correlation between plasma glucose and hemoglobin A1c. In patients with hemoglobin Himeji, alternate ways of monitoring glycemic control (fructosamine or glycated serum albumin) should be used.
糖化血红蛋白用于评估糖尿病患者的血糖控制情况,是糖尿病慢性并发症的风险标志物。据报道,血红蛋白变异体会错误地降低或升高糖化血红蛋白检测结果。我们报告一例糖尿病患者,由于存在姬路血红蛋白(一种临床无症状且非常罕见的血红蛋白病),其空腹血糖与糖化血红蛋白之间存在差异。
一名76岁的白人女性,出生并居住在葡萄牙,患有2型糖尿病,因常规就诊前往家庭医生处。她没有任何活动性不适,包括低血糖病史或症状,体格检查无异常。对其实验室数据的回顾显示,空腹血糖为190mg/dL,糖化血红蛋白为4.1%。其余血液检测结果在临床上无显著意义;对其过去4年实验室数据的进一步回顾显示,她的空腹血糖范围为130至250mg/dL,糖化血红蛋白始终低于5%。血红蛋白研究检测到32.8%的异常血红蛋白。基因测序确定了一个与姬路血红蛋白相符的杂合突变(c.422C>A;p.Ala141Asp)。我们追踪了她的家族(三个儿子、六个孙子和两个曾孙)是否存在这种血红蛋白变异,但没有人患有这种血红蛋白病。
尽管糖化血红蛋白在糖尿病的随访和治疗中具有优势,但必须了解干扰其结果的因素,以确保正确估计血糖控制程度并对疾病进行适当管理。因此,当出现以下情况时,卫生专业人员应怀疑存在血红蛋白变异:糖化血红蛋白值高于15%或低于其参考区间下限;其结果出现显著变化且与检测方法的改变同时发生;血浆葡萄糖与糖化血红蛋白之间的相关性较低。对于患有姬路血红蛋白的患者,应使用其他监测血糖控制的方法(果糖胺或糖化血清白蛋白)。